WO2012036329A1 - 간암 예후 예측용 조성물 또는 키트, 및 간암 예후 예측 방법 - Google Patents

간암 예후 예측용 조성물 또는 키트, 및 간암 예후 예측 방법 Download PDF

Info

Publication number
WO2012036329A1
WO2012036329A1 PCT/KR2010/006357 KR2010006357W WO2012036329A1 WO 2012036329 A1 WO2012036329 A1 WO 2012036329A1 KR 2010006357 W KR2010006357 W KR 2010006357W WO 2012036329 A1 WO2012036329 A1 WO 2012036329A1
Authority
WO
WIPO (PCT)
Prior art keywords
prognosis
liver cancer
making
kit
composition
Prior art date
Application number
PCT/KR2010/006357
Other languages
English (en)
French (fr)
Inventor
박진영
홍석주
김종민
Original Assignee
씨비에스바이오사이언스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨비에스바이오사이언스 주식회사 filed Critical 씨비에스바이오사이언스 주식회사
Priority to CN201080069658.8A priority Critical patent/CN103562404A/zh
Priority to CN201510633969.7A priority patent/CN105223357A/zh
Priority to US13/823,718 priority patent/US9963746B2/en
Priority to PCT/KR2010/006357 priority patent/WO2012036329A1/ko
Publication of WO2012036329A1 publication Critical patent/WO2012036329A1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

본 발명은 간암 예후 예측용 마커, 간암 예후 예측용 조성물 또는 키트, 바 람직하게는 간암 병기별 예후 예측을 위한 간암 예후 예측용 조성물 또는 키트와 간암 예후 예측방법을 제공한다. 본 발명의 마커, 조성물 또는 키트, 방법에 의해 효과적으로 간암 예후 예측, 바람직하게는 병기별 간암 예후 예측이 가능하다.
PCT/KR2010/006357 2010-09-16 2010-09-16 간암 예후 예측용 조성물 또는 키트, 및 간암 예후 예측 방법 WO2012036329A1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201080069658.8A CN103562404A (zh) 2010-09-16 2010-09-16 预测肝癌预后的组合物或试剂盒以及预测肝癌预后的方法
CN201510633969.7A CN105223357A (zh) 2010-09-16 2010-09-16 预测肝癌预后的组合物或试剂盒
US13/823,718 US9963746B2 (en) 2010-09-16 2010-09-16 Composition or kit for making a prognosis of liver cancer, and method for making a prognosis of liver cancer
PCT/KR2010/006357 WO2012036329A1 (ko) 2010-09-16 2010-09-16 간암 예후 예측용 조성물 또는 키트, 및 간암 예후 예측 방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/006357 WO2012036329A1 (ko) 2010-09-16 2010-09-16 간암 예후 예측용 조성물 또는 키트, 및 간암 예후 예측 방법

Publications (1)

Publication Number Publication Date
WO2012036329A1 true WO2012036329A1 (ko) 2012-03-22

Family

ID=45831771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006357 WO2012036329A1 (ko) 2010-09-16 2010-09-16 간암 예후 예측용 조성물 또는 키트, 및 간암 예후 예측 방법

Country Status (3)

Country Link
US (1) US9963746B2 (ko)
CN (2) CN105223357A (ko)
WO (1) WO2012036329A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103920150A (zh) * 2014-04-17 2014-07-16 北京大学第一医院 Satb1在治疗皮肤t细胞淋巴瘤中的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101843173B1 (ko) * 2014-10-24 2018-03-29 씨비에스바이오사이언스 주식회사 혈관 내피 세포 성장인자 수용체 억제제에 대한 감수성 예측 방법
JP6793451B2 (ja) * 2014-11-14 2020-12-02 キヤノンメディカルシステムズ株式会社 被検細胞の細胞特性を評価するための遺伝子マーカー、方法、レポーターベクター、プライマーセットおよびアッセイキット、並びに細胞特性評価装置
CN110205369A (zh) * 2019-04-01 2019-09-06 东莞市第八人民医院（东莞市儿童医院） 一种用于定量检测STAT3 mRNA水平的引物、探针和试剂盒
CN111041027B (zh) * 2019-12-19 2022-10-28 广东省农业科学院动物卫生研究所 一种Atg12基因敲除细胞系构建方法及其应用
CN113215198B (zh) * 2021-04-07 2023-09-22 浙江安各洛生物技术有限公司 一种重组杆状病毒及其制备方法和应用
CN115786356B (zh) * 2022-11-17 2023-06-30 百世诺（北京）医疗科技有限公司 致心律失常右室发育不良心肌病变异基因cdh2及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046808B (zh) * 2008-05-27 2017-05-17 丹麦达科有限公司 使用新的杂交缓冲液用于检测染色体畸变的组合物和方法
CN101509035A (zh) 2008-09-05 2009-08-19 中国人民解放军总医院 肺癌分型的基因序列及其应用
KR100964193B1 (ko) 2009-04-17 2010-06-16 씨비에스바이오사이언스 주식회사 간암 예후 마커

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
VILLANUEVA ET AL.: "New strategies in hepatocellular carcinoma: genomic prognostic markers", CLINICAL CANCER RESEARCH., vol. 16, no. 19, 16 August 2010 (2010-08-16), pages 4688 - 4694 *
WANG ET AL.: "Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome", HEPATOLOGY., vol. 52, no. 1, July 2010 (2010-07-01), pages 164 - 173 *
XU ET AL.: "Expression and prognostic significance of placental growth fctor in hepatocellular carcinoma and peritumoral liver tissue", INTERNATIONAL JOURNAL OF CANCER., vol. 128, no. 7, 2 June 2010 (2010-06-02), pages 1559 - 1569 *
ZHANG ET AL.: "Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems", EUROPEAN JOURNAL OF SURGICAL ONCOLOGY., vol. 36, no. 8, 9 June 2010 (2010-06-09), pages 718 - 724 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103920150A (zh) * 2014-04-17 2014-07-16 北京大学第一医院 Satb1在治疗皮肤t细胞淋巴瘤中的应用

Also Published As

Publication number Publication date
CN103562404A (zh) 2014-02-05
CN105223357A (zh) 2016-01-06
US20140162889A1 (en) 2014-06-12
US9963746B2 (en) 2018-05-08

Similar Documents

Publication Publication Date Title
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
WO2012006476A3 (en) Methods and compositions for quantifying exosomes
MX353579B (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
WO2012036329A1 (ko) 간암 예후 예측용 조성물 또는 키트, 및 간암 예후 예측 방법
WO2012058211A3 (en) Quinazoline derivatives, compositions, and uses related thereto
ZA201203603B (en) Lyophilization methods, compositions, and kits
WO2011156654A3 (en) Pathways characterization of cells
WO2008089397A3 (en) Adrb2 cancer markers
WO2012099930A3 (en) Flavonol compositions
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2008116220A3 (en) Methods and compositions related to riboswitches that control alternative splicing
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
PL2658444T3 (pl) Sposób dostarczania wydajnego biosensora oraz odpowiedni biosensor, podłoże i zestaw do wprowadzania
WO2013130963A8 (en) Compositions and methods for treating type iii gaucher disease
EP2601235A4 (en) EPOXYED COMPOSITION AND METHOD OF MANUFACTURING THEREOF
WO2013025322A3 (en) Marker-based prognostic risk score in liver cancer
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
MX2009012647A (es) Metodos y composiciones relacionadas con ribointerruptores que controlan la separacion alternativa y proceso de arn.
WO2011100642A3 (en) Method for treating hematological cancers
WO2012167163A3 (en) Methods and compositions for detecting endometrial or ovarian cancer
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
WO2014037519A3 (en) Compositions and methods
WO2012061086A3 (en) Method of treating neuroendocrine tumors
WO2013093627A3 (en) In silico affinity maturation
WO2012051126A3 (en) Anti-inflammatory macrolides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10857314

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13823718

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10857314

Country of ref document: EP

Kind code of ref document: A1